Wednesday, September 06, 2023
Image
![NIH Default Logo](/sites/default/files/styles/half_width_small/public/2020-10/news-default.png?itok=rPIuiSJC)
AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced results from the company's REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.